SFX by Ex Libris Inc.

Title:	Novel Cell- and Tissue-Based Assays for Detecting Misfolded and Aggregated Protein Accumulation Within Aggresomes and Inclusion Bodies
Source:	Cell Biochemistry and Biophysics [1085-9195] Shen, Dee yr:2010

Basic

Full text

Full text available via SpringerLINK Contemporary 1997-Present

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Kickstein, Sybille a. "Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling." Proceedings of the National Academy of Sciences of the United States of America 107.50 (2010): 21830-5.
description	2.	Gupta, A. "Peripheral insulin-sensitizer drug Metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes." Neuropharmacology 60.6 (2011): 910-920.
description	3.	Hawley, Simon A. "Use of Cells Expressing gamma Subunit Variants to Identify Diverse Mechanisms of AMPK Activation." Cell metabolism 11.6 (2010): 554-565.
description	4.	Caccamo, A. "Molecular interplay between mTOR, A{beta} and tau: Effects on cognitive impairments." The Journal of biological chemistry 285.17 (2010): 13107-13120.
description	5.	Zhou, X. "Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A." Neurobiology of disease 314.3 (2008): 386-394.
description	6.	Balfour, J A A. "Rosiglitazone." Drugs 57.6 (1999): 921-30.
description	7.	"Rosiglitazone." Diabetes, obesity & metabolism 2.2 (2000): 117-117.
description	8.	Simon, D. Primary care diabetes 3.2 (2009): 123-124.
description	9.	Sels, Bruce P. Expert opinion on pharmacotherapy 2.3 (2001): 467-78.
description	10.	Foretz, M. "Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state." Journal of Clinical Investigation 120.7 (2010): 2355-2369.
description	11.	Liu, R. "Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology." Journal of Cellular and Molecular Medicine 12.1 (2008): 241-257.
description	12.	Sakurai, H. "Vascular risk factors and progression in Alzheimer's disease." Geriatrics and gerontology international 11.2 (2010): 211-214.
description	13.	Akter, K. "Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?" British journal of clinical pharmacology 71.3 (2011): 365-376.
description	14.	Breteler, Schrijvers B. "Insulin metabolism and the risk of Alzheimer disease: The Rotterdam Study." Neurology 75.22 (2010): 1982-1987.
description	15.	Carter, M D. "The development of new therapeutics for Alzheimer's disease." Clinical pharmacology & therapeutics 88.4 (2010): 475-486.
description	16.	Caccamo, A. "Rapamycin rescues TDP-43 mislocalization and the associated low molecular mass neurofilament instability." The Journal of biological chemistry 284.40 (2009): 27416-27424.
description	17.	Venkataramani, V. "Histone Deacetylase Inhibitor Valproic Acid Inhibits Cancer Cell Proliferation via Down-regulation of the Alzheimer Amyloid Precursor Protein." The Journal of biological chemistry 285.14 (2010): 10678-10689.
description	18.	Jellinger, Kurt A. "Recent advances in our understanding of neurodegeneration." Journal of Neural Transmission 116.9 (2009): 1111-1162.
description	19.	Pei, J. "mTOR-dependent signalling in Alzheimer's disease." Journal of Cellular and Molecular Medicine 12.6B (2008): 2525-32.
description	20.	Zhou XW, Tanila H, Pei JJ;, Xin-Wen W. "Parallel increase in p70 kinase activation and tau phosphorylation (S262) with Abeta overproduction." FEBS letters 582.2 (2007): 159-64.